Xencor (NASDAQ:XNCR) will issue its Q2 2019 quarterly earnings data after the market closes on Tuesday, August 6th. Analysts expect the company to announce earnings of ($0.45) per share for the quarter.
Xencor (NASDAQ:XNCR) last released its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported $1.38 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.43 by $0.95. The firm had revenue of $111.94 million during the quarter, compared to the consensus estimate of $60.05 million. On average, analysts expect Xencor to post $0 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
XNCR traded down $1.34 during trading on Monday, hitting $43.34. The stock had a trading volume of 2,043 shares, compared to its average volume of 385,492. The stock has a 50 day simple moving average of $41.44. The company has a market capitalization of $2.52 billion, a price-to-earnings ratio of -34.11 and a beta of 1.39. Xencor has a one year low of $27.75 and a one year high of $48.38. The company has a current ratio of 6.66, a quick ratio of 6.66 and a debt-to-equity ratio of 0.02.
Several research firms recently issued reports on XNCR. BidaskClub upgraded Xencor from a “strong sell” rating to a “sell” rating in a research note on Thursday, June 20th. Zacks Investment Research upgraded Xencor from a “strong sell” rating to a “hold” rating in a research note on Saturday, July 20th. ValuEngine upgraded Xencor from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, July 2nd. Mizuho restated a “buy” rating and issued a $52.00 price target on shares of Xencor in a research note on Monday, July 1st. Finally, Guggenheim started coverage on Xencor in a research note on Friday, April 12th. They issued a “buy” rating and a $42.00 price target for the company. Two investment analysts have rated the stock with a sell rating, one has given a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $43.44.
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.
Read More: Market Perform
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.